Xilio Therapeutics (XLO) Times Interest Earned (2020 - 2026)
Xilio Therapeutics (XLO) posted Times Interest Earned of -$742.74 for Q1 2026, down 69.43% sequentially from -$438.37 in Q4 2025, and down 216.38% YoY from $638.21 in Q1 2025.
Xilio Therapeutics (XLO) Times Interest Earned (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Times Interest Earned for 7 years, with the latest figure at -$742.74 in Q1 2026.
- Quarterly Times Interest Earned fell 216.38% year-over-year to -$742.74 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2223.3 (down 130.35% YoY) and the FY2025 annual result came in at -$0.33, up 37.84% from the prior year.
- Times Interest Earned declined to -$742.74 in Q1 2026 per XLO's latest filing, from -$438.37 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$18.47 in Q4 2022 and troughed at -$742.74 in Q1 2026.
- A 5-year average of -$194.96 and a median of -$106.12 in 2022 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 90.55% in 2022, down 9030.53% in 2022.
- Over 5 years, Times Interest Earned stood at -$18.47 in 2022, then slumped by 334.23% to -$80.22 in 2023, then surged by 39.75% to -$48.33 in 2024, then plunged by 807.04% to -$438.37 in 2025, then plunged by 69.43% to -$742.74 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$742.74, -$438.37, and -$28.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.06 |
| Mar 31, 2026 | -742.74 |
| Dec 31, 2025 | -438.37 |
| Sep 30, 2025 | -28.37 |
| Jun 30, 2025 | -368.36 |
| Mar 31, 2025 | -234.76 |
| Dec 31, 2024 | -48.33 |
| Sep 30, 2024 | -149.11 |
| Jun 30, 2024 | -84.02 |
| Mar 31, 2024 | -55.69 |
| Dec 31, 2023 | -80.22 |
| Sep 30, 2023 | -403.74 |
| Jun 30, 2023 | -261.25 |
| Mar 31, 2023 | -112.56 |
| Dec 31, 2022 | -18.47 |
| Sep 30, 2022 | -92.26 |
| Jun 30, 2022 | -89.93 |
| Mar 31, 2022 | -106.12 |
| Dec 31, 2021 | -195.56 |
| Sep 30, 2021 | -1.01 |